Načrtovanje, sinteza in vrednotenje nitro derivatov 5-stirilnikotinonitrila kot zaviralcev monoamin oksidaze

Kovše, Monika (author), Frlan, Rok (mentor)

Monoamin oksidaza (MAO) je flavoencim, vezan na zunanjo mitohondrijsko membrano, ki katalizira reakcijo oksidativne deaminacije aminov. V telesu uravnava homeostazo in prenos signalov pomembnih monoaminskih nevrotransmitorjev, kot so serotonin, dopamin in noradrenalin. Ločimo dva izoencima, monoamin oksidazo A (MAO-A) in monoamin oksidazo B (MAO-B), ki se med sabo razlikujeta po selektivnosti za substrat, občutljivosti na zaviralce in porazdelitvi po tkivih. Zvečano aktivnost MAO in posledično znižane koncentracije monoaminskih nevrotransmitorjev povezujejo s številnimi nevrološkimi motnjami, hkrati pa pri reakciji oksidativne deaminacije nastajajo nevrotoksični produkti, ki prispevajo k oksidativnim poškodbam. Zaviralci MAO se zato že desetletja uporabljajo v terapiji številnih bolezni, kot so depresija, Parkinsonova bolezen in Alzheimerjeva bolezen. Prvi zaviralci MAO so bili neselektivni in ireverzibilni, danes pa razvoj stremi k selektivnim in reverzibilnim zaviralcev, saj ti povzročajo manj neželenih učinkov. Laboratorijsko delo je obsegalo sintezo in vrednotenje nitro derivatov 5-stirilnikotinonitrila. Spojine smo načrtovali na podlagi predhodnega raziskovanja potencialnih zaviralcev MAO na Katedri za farmacevtsko kemijo Fakultete za farmacijo Univerze v Ljubljani in na podlagi strukture znanega reverzibilnega zaviralca MAO-B safinamida. Zaviralno aktivnost spojin smo ovrednotili z biološkimi testiranji na humanih encimih MAO-A in MAO-B. Od skupno 16 testiranih spojin smo srednjo zaviralno aktivnost (IC50) v nanomolarnem območju določili osmim spojinam v primeru izoencima MAO-B in eni spojini v primeru izoencima MAO-A. Najboljše zaviralne sposobnosti sta izkazovali spojini (E)-2-kloro-5-(4-metoksi-2-nitrostiril)nikotinonitril (IC50 = 42.2 ± 4.9 nM) in etil (E)-2-(4-(2-(5-cianopiridin-3-il)vinil)-3-nitrofenoksi)acetat (IC50 = 42.3 ± 3.4 nM) na MAO-B izoencimu. Te vrednosti presegajo zaviralne sposobnosti safinamida (IC50 = 98 nM) in predstavljajo dobro usmeritev za nadaljnje raziskovanje zaviralcev MAO.

• Language: Slovenian
• Keywords: monoamin oksidaza, MAO, zaviralci, nevrodegenerativne bolezni, Parkinsonova bolezen
• Work type: Master's thesis/paper
• Organization: FFA - Faculty of Pharmacy
• Year: 2021
• PID: 20.500.12556/RUL-127827
• Publication date in RUL: 24.06.2021

Secondary language

• Language: English
• Title: Design, synthesis and evaluation of nitro derivatives of 5-styrylnicotinonitrile as monoamine oxidase inhibitors

Abstract

Monoamine oxidase (MAO) is a flavoenzyme bound to the outer mitochondrial membrane, which catalyzes the oxidative deamination of amines. MAO regulates homeostasis and neurotransmission of important monoamine neurotransmitters like serotonin, dopamine and noradrenalin. There are two isoenzymes, monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), which differ in their substrate specificities, inhibitor sensitivities and tissue localization. Increased activity of MAO, followed by decreased concentrations of monoamine neurotransmitters, is related to numerous neurological disorders. During the reaction of oxidative deamination several neurotoxic species are produced, which contribute to the oxidative damage. MAO inhibitors have been therefore used for decades in the treatment of numerous diseases like depression, Parkinson’s disease and Alzheimer’s disease. The first MAO inhibitors were non-selective and irreversible, but recently the research focused on the development of reversible and selective MAO inhibitors due to the lower degree of adverse effects. The laboratory work involved the synthesis and evaluation of nitro derivatives of 5-styrylnicotinonitrile. Compounds were designed based on previous research of potential MAO inhibitors at the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, and based on the structure of known reversible MAO-B inhibitor safinamide. The inhibitory activity of compounds was evaluated with biological tests on human MAO-A and MAO-B enzymes. Out of a total of 16 tested compounds, the half maximal inhibitory concentration (IC50) in nanomolar region was determined by eight compounds in the case of MAO-B and by one compound in the case of MAO-A isoenzyme. Two compounds showed the best inhibitory properties: (E)-2-chloro-5-(4-methoxy-2-nitrostyryl)nicotinonitrile (IC50 = 42.2 ± 4.9 nM) and etil (E)-2-(4-(2-(5-cyanopyridin-3-yl)vinyl)-3-nitrophenoxy)acetate (IC50 = 42.3 ± 3.4 nM) on MAO-B isoenzyme. These values exceed the inhibitory property of safinamide (IC50 = 98 nM) and present a basis of further research of MAO inhibitors.

• Keywords: monoamine oxidase, MAO, inhibitors, neurodegenerative diseases, Parkinson’s disease